AR-712 / Aridis - LARVOL DELTA

Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant (PRNewswire) - "...AR-712 binds and neutralizes the Delta variant virus SARS-CoV-2 at a highly effective level (~20ng/mL). Binding analyses project that AR-712 will be effective against all variants on the U.S. Centers for Disease Control's Variants of Interest and Variants of Concern lists....Aridis is pleased to announce the preclinical development services support from NIAID (NIH) provided further demonstration of strong therapeutic efficacy of inhaled delivery in a SARS-CoV-2 hamster challenge model. This achieved reversal of disease in infected animals at an inhaled dose of 1mg/kg, equivalent to a 10mg dose in humans from a nebulizer."

Preclinical • Infectious Disease • Novel Coronavirus Disease

Aridis Pharmaceuticals Announces First Quarter 2021 Results (PRNewswire) - "The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering. A clinical Phase 1/2 study is expected to be launched in 2H 2021....AR-301 is being evaluated in a Phase 3 clinical study as an adjunctive treatment to standard of care antibiotics in S. aureus infected ventilator associated pneumonia (VAP) patients....The Phase 3 interim futility analysis from the ongoing pivotal trial is now expected to be reported in 2H 2021 and top line data by 1H 2022."

New P1/2 trial • P3 data: top line • Infectious Disease • Novel Coronavirus Disease